User profiles for Matthew Buras

Matthew R. Buras

Mayo Clinic
Verified email at mayo.edu
Cited by 2771

Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients

…, KF Larson, JG Ripoll, KJ Andersen, MR Buras… - Mayo Clinic …, 2020 - Elsevier
Objective To provide an update on key safety metrics after transfusion of convalescent plasma
in hospitalized coronavirus 2019 (COVID-19) patients, having previously demonstrated …

[HTML][HTML] Early safety indicators of COVID-19 convalescent plasma in 5000 patients

…, DO Hodge, KL Kunze, MR Buras… - The Journal of …, 2020 - Am Soc Clin Investig
BACKGROUND Convalescent plasma is the only antibody-based therapy currently available
for patients with coronavirus disease 2019 (COVID-19). It has robust historical precedence …

[HTML][HTML] Convalescent plasma antibody levels and the risk of death from Covid-19

…, JG Ripoll, KJ Andersen, MR Buras… - … England Journal of …, 2021 - Mass Medical Soc
Background Convalescent plasma has been widely used to treat coronavirus disease 2019 (Covid-19)
under the presumption that such plasma contains potentially therapeutic …

[HTML][HTML] Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study

…, BH Shaz, MM Petersen, BS Sachais, MR Buras… - PLoS …, 2021 - journals.plos.org
Background The United States (US) Expanded Access Program (EAP) to coronavirus disease
2019 (COVID-19) convalescent plasma was initiated in response to the rapid spread of …

[HTML][HTML] Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors

…, KA Bruno, JR Mills, ES Theel, MR Buras… - Nature …, 2021 - nature.com
Successful therapeutics and vaccines for coronavirus disease 2019 (COVID-19) have
harnessed the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-…

[HTML][HTML] Rates among hospitalized patients with COVID-19 treated with Convalescent plasma: A systematic review and meta-analysis

…, SA Parikh, SE Baker, ZA Buchholtz, MR Buras… - … : Innovations, Quality & …, 2023 - Elsevier
Objective To examine the association of COVID-19 convalescent plasma transfusion with
mortality and the differences between subgroups in hospitalized patients with COVID-19. …

Capsule retention in Crohn's disease: a meta-analysis

…, E Rondonotti, D Wolf, MR Buras… - Inflammatory bowel …, 2020 - academic.oup.com
Background The main factor that limits wider utilization of capsule endoscopy (CE) in Crohn’s
disease (CD) is the potential risk of retention. The aim of this systematic review was to …

Treatment outcomes of squamous cell carcinoma of the oral cavity in young adults

…, JCM Rwigema, LA McGee, MY Halyard, MR Buras… - Oral oncology, 2018 - Elsevier
Objectives The natural history of squamous cell carcinoma (SCC) of the oral cavity (OC) in
young adults is unknown. We sought to provide an updated report on treatment outcomes of …

[HTML][HTML] A multi-institutional experience of proton beam therapy for sinonasal tumors

…, CB Simone II, C Rossi, SR Katz, MR Buras… - Advances in Radiation …, 2019 - Elsevier
Purpose To report the outcomes of sinonasal tumors treated with proton beam therapy (PBT)
on the Proton Collaborative Group registry study. Methods and Materials Sixty-nine patients …

Artificial intelligence trumps TAVI2-SCORE and CoreValve score in predicting 1-year mortality post-transcatheter aortic valve replacement

…, A Tseng, F Mookadam, NR Venepally, M Buras… - Cardiovascular …, 2021 - Elsevier
Background/purpose Machine learning has been used to predict procedural risk in patients
undergoing various medical interventions and procedures. One-year mortality in patients …